The National Medical Products Administration (NMPA) has granted marketing approval to China-based Jiangsu Bioda Life Science Co Ltd’s innovative artificial blood vessel. This marks a significant milestone in the development and commercialization of advanced medical devices in China.
Product Profile
The artificial blood vessel is primarily composed of PET thread and is coated with bovine collagen and glycerin. The product features an innovative knitting process that results in smaller and more uniform pores in the polyester weaving. This design is expected to enhance the bleeding performance of the finished product, making it suitable for replacement or bypass operations of the aorta and its branches.
Market and Clinical Implications
The approval by the NMPA positions Jiangsu Bioda Life Science to expand its market presence in the field of cardiovascular medical devices. The innovative design of the artificial blood vessel aims to improve surgical outcomes and patient recovery, addressing critical needs in vascular surgery. This development underscores the company’s commitment to advancing medical technology and improving patient care.-Fineline Info & Tech
